Literature DB >> 35902775

Activation and regulation of alloreactive T cell immunity in solid organ transplantation.

Charlotte Duneton1,2, Pamela D Winterberg3, Mandy L Ford4.   

Abstract

Transplantation is the only curative treatment for patients with kidney failure but it poses unique immunological challenges that must be overcome to prevent allograft rejection and ensure long-term graft survival. Alloreactive T cells are important contributors to graft rejection, and a clearer understanding of the mechanisms by which these cells recognize donor antigens - through direct, indirect or semi-direct pathways - will facilitate their therapeutic targeting. Post-T cell priming rejection responses can also be modified by targeting pathways that regulate T cell trafficking, survival cytokines or innate immune activation. Moreover, the quantity and quality of donor-reactive memory T cells crucially shape alloimmune responses. Of note, many fundamental concepts in transplant immunology have been derived from models of infection. However, the programmed differentiation of allograft-specific T cell responses is probably distinct from that of pathogen-elicited responses, owing to the dearth of pathogen-derived innate immune activation in the transplantation setting. Understanding the fundamental (and potentially unique) immunological pathways that lead to allograft rejection is therefore a prerequisite for the rational development of therapeutics that promote transplantation tolerance.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35902775     DOI: 10.1038/s41581-022-00600-0

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   42.439


  135 in total

1.  Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question.

Authors:  E J Suchin; P B Langmuir; E Palmer; M H Sayegh; A D Wells; L A Turka
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

2.  CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.

Authors:  B A Pietra; A Wiseman; A Bolwerk; M Rizeq; R G Gill
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection.

Authors:  D W Talmage; G Dart; J Radovich; K J Lafferty
Journal:  Science       Date:  1976-01-30       Impact factor: 47.728

4.  High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules.

Authors:  J D Ashwell; C Chen; R H Schwartz
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

5.  Recognition requirements for the activation, differentiation and function of T-helper cells specific for class I MHC alloantigens.

Authors:  A Singer; T I Munitz; H Golding; A S Rosenberg; T Mizuochi
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

Review 6.  The molecular basis of allorecognition.

Authors:  L A Sherman; S Chattopadhyay
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

7.  Donor pretreatment: rat heart allograft survival and measurement of passenger leukocyte depletion with indium-111.

Authors:  S Oluwole; M A Hardy; T Wang; K Satake; G Todd; K Reemtsma; R Nowygrod
Journal:  Transplantation       Date:  1980-07       Impact factor: 4.939

8.  Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection.

Authors:  C P Larsen; P J Morris; J M Austyn
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

9.  Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells.

Authors:  R I Lechler; J R Batchelor
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Cellular requirements for renal allograft rejection in the athymic nude rat.

Authors:  E M Bolton; J A Gracie; J D Briggs; J Kampinga; J A Bradley
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.